Kythera Biopharmaceuticals, Inc. has received regulatory approval in Canada to sell its drug that dissolves chin fat, the company announced Monday.

The Westlake Village biotech will market the double-chin treatment under the name Belkyra. The drug received approval from the Food and Drug Administration for sale in the U.S. in April. In the U.S., the drug is sold under the brand name Kybella.

“The authorization of Belkyra in Canada is another milestone for Kythera and for physicians who now have a treatment for fat under the chin,” Chief Executive Keith Leonard said in a statement.

In June, Allergan plc in Dublin, Ireland announced it would buy Kythera for $2.1 billion. Allergan expects to complete the buyout before the end of the third quarter, pending Kythera shareholder approval.

Kythera shares closed up 24 cents or a fraction of a percent to $74.41 on the Nasdaq.